| Name | Title | Contact Details |
|---|
Impact Advisors is a nationally recognized healthcare consulting firm that is solving some of the toughest challenges in the industry by delivering strategic advisory, implementation and optimization services. Our comprehensive suite of patient access, clinical and revenue cycle services span the lifecycle of our clients` needs. Our experienced team has a powerful combination of clinical, revenue, operations, consulting, and IT experience. The firm has earned a number of prestigious industry and workplace awards including Best in KLAS® for thirteen consecutive years, Healthcare Informatics HCI 100, Crain`s Chicago Business Fast Fifty, as well as multi-year “best place to work” awards from: Modern Healthcare, Consulting Magazine, Becker`s Hospital Review and Achievers.
On Assignment, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
nTELAGENT, Inc is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Petaluma Health Care District is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.